Kasiani Myers, MD | Aplastic Anemia and ...

Dr. Kasiani Myers, MD

Claim this profile

Cincinnati Children's Hospital Medical Center

Studies Bone Marrow Failure Syndrome
Studies Bone Marrow Failure
5 reported clinical trials
9 drugs studied

Area of expertise

1

Bone Marrow Failure Syndrome

Kasiani Myers, MD has run 3 trials for Bone Marrow Failure Syndrome. Some of their research focus areas include:

SAMD9 positive
SAMD9L positive
GATA2 positive
2

Bone Marrow Failure

Kasiani Myers, MD has run 2 trials for Bone Marrow Failure.

Affiliated Hospitals

Image of trial facility.

Cincinnati Children's Hospital Medical Center

Image of trial facility.

Cincinnati Children's Hospital

Clinical Trials Kasiani Myers, MD is currently running

Image of trial facility.

Ruxolitinib

for Lung Dysfunction Post Stem Cell Transplant

Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy, and lung injury affects as many as 25% of children receiving HSCT. Improved transplant techniques and major improvements in survival mean that HSCT is being more widely used, and more mismatched grafts are being used. Bronchiolitis obliterans (BO) is a major limitation of pediatric HSCT success as BO is commonly diagnosed late in children, when lung injury is irreversible, leading to long term morbidity or even death. Currently, there are major gaps in our knowledge regarding incidence, etiology and optimal treatment of BO following HSCT, and important diagnostic limitations specific to children. Diagnosis of BO is usually based on performance of pulmonary function tests, which is usually impossible in ill children under 10. Even older children who feel unwell or un-cooperative may be unable to produce interpretable data. These deficiencies in diagnosis mean that BO is commonly diagnosed late, meaning fibrosis has occurred and lesions are irreversible. The hypothesis for this interventional trial is that early treatment with standard Flovent/montelukast and steroids plus ruxolitinib will reverse lung injury and reduce the frequency of chronic pulmonary impairment or florid BO.

Recruiting

1 award

Phase 2

4 criteria

Image of trial facility.

EXG34217

for Bone Marrow Failure

This trial tests the safety and tolerability of EXG34217 in patients with bone marrow failure due to telomere biology disorders. The treatment involves collecting, processing, and reinfusing the patient's own blood cells to help improve their bone marrow function.

Recruiting

1 award

Phase 1

3 criteria

More about Kasiani Myers, MD

Clinical Trial Related

3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Kasiani Myers, MD has experience with

  • EXG34217
  • Fludarabine
  • Alemtuzumab
  • Cyclosporins
  • Mycophenolate Mofetil
  • Tacrolimus

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Kasiani Myers, MD specialize in?

Is Kasiani Myers, MD currently recruiting for clinical trials?

Are there any treatments that Kasiani Myers, MD has studied deeply?

What is the best way to schedule an appointment with Kasiani Myers, MD?

What is the office address of Kasiani Myers, MD?

Is there any support for travel costs?